C

Checkpoint Therapeutics
D

CKPT

4.01000
USD
0.27
(7.22%)
Market Closed
Volume
0
EPS
-1
Div Yield
-
P/E
-2
Market Cap
195,818,325
OverviewSignalsIdeasNews
Related Instruments
    ABBV
    ABBV
    -4.630
    (-2.73%)
    165.020 USD
    AMGN
    AMGN
    -12.22
    (-4.13%)
    283.72 USD
    AZN
    AZN
    -1.830
    (-2.81%)
    63.220 USD
    BMY
    BMY
    -2.270
    (-3.88%)
    56.230 USD
    GSK
    GSK
    -1.020
    (-2.97%)
    33.350 USD
    JNJ
    JNJ
    2.140
    (1.41%)
    154.020 USD
    MRK
    MRK
    -2.050
    (-2.08%)
    96.290 USD
    NVS
    NVS
    -0.350
    (-0.34%)
    103.070 USD
    PFE
    PFE
    -1.225
    (-4.71%)
    24.800 USD
    SNY
    SNY
    0.160
    (0.33%)
    47.980 USD
    More
News

Title: Checkpoint Therapeutics

Sector: Healthcare
Industry: Biotechnology
Checkpoint Therapeutics Inc is an immuno-oncology biopharmaceutical company based in the USA. It focuses on the acquisition, development, and commercialization of novel, non-chemotherapy, immune-enhanced combination treatments for patientswith solid tumor cancers. Its licensed portfolio of antibodies includes targeting programmed cell death-ligand 1 (PD-L1), glucocorticoid-induced TNFR-related protein (GITR) and carbonic anhydrase IX (CAIX). The company is evaluating its lead small-molecule, targeted anti-cancer agent, olafertinib, a third-generation epidermal growth factor receptor ("EGFR") inhibitor, as a potential new treatment for patients with EGFR mutation-positive non-small cell lung cancer.